BioCentury | Apr 18, 2016
Clinical News

Durvalumab: Phase I/II started

The CVC Trials Network began an open-label, dose-escalation, international Phase I/II trial to evaluate subcutaneous motolimod ( VTX-2337 ), IV durvalumab and IV pegylated liposomal doxorubicin (PLD) in 28-day cycles in about 53 patients. For the...
BioCentury | Apr 18, 2016
Clinical News

Motolimod: Phase I/II started

The CVC Trials Network began an open-label, dose-escalation, international Phase I/II trial to evaluate subcutaneous motolimod, IV durvalumab ( MEDI4736 ) and IV pegylated liposomal doxorubicin (PLD) in 28-day cycles in about 53 patients. For the first...
BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: Phospholipase D2 (PLD2)

...sepsis. In two mouse models of sepsis, PLD2 knockout or a tool compound that inhibited PLD2...
...increased survival compared with normal PLD2 expression or vehicle, respectively. In one of the models, PLD2...
...normal PLD2 expression. Next steps could include testing PLD2 inhibition in additional sepsis models. TARGET/MARKER/PATHWAY: Phospholipase D2 (PLD2)...
BioCentury | Aug 27, 2015
Distillery Therapeutics

Therapeutics: Phospholipase D1 (PLD1)

Cancer INDICATION: Colorectal cancer Mouse and patient sample studies suggest inhibiting PLD1 could help treat colorectal cancer. In colorectal cancer patients, levels of PLD1 mRNA were higher in tumors than in surrounding normal tissues and...
BioCentury | Jan 30, 2014
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Phospholipase D3 (PLD3) Human sample and in vitro studies suggest stimulating PLD3 activity could help treat a subset...
BioCentury | Jan 13, 2011
Distillery Therapeutics

Indication: Neurology

...Publication and contact information Neurology Alzheimer's disease (AD) Phospholipase D2 (PLD2) Studies in mice suggest that inhibiting PLD2...
...help prevent b-amyloid (Ab)-associated toxicity to treat AD. In a transgenic mouse model of AD, Pld2...
...led to improvements in memory compared with no Pld2 deficiency (p<0.01). Next steps include developing PLD2-specific...
BioCentury | May 6, 2010
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Ophthalmic disease Phospholipase D1, phosphatidylcholine-specific (PLD1); protein kinase C γ (PRKCG) In vitro and mouse studies suggest that inhibiting PLD1 or PRKCG could prevent...
BioCentury | Jan 29, 2009
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Phospholipase D (PLD); PLD1; PLD2...
...has been implicated in multiple human cancers. A dual inhibitor of PLD isoforms PLD1 and PLD2...
...line. Next steps could include additional studies to better define the role of PLD1 and PLD2...
BioCentury | Jun 26, 2006
Company News

Wilex management update

Wilex AG , Munich, Germany Business: Cancer Resigned: Niels Ackermann as CFO and a director to join to join the global capitol market department of Morgan Stanley Inc. Hired: Peter Llewellyn-Davies as acting CFO, while remaining...
BioCentury | Jun 20, 2006
Company News

Ackermann leaving Wilex as CFO

Cancer company Wilex (Munich, Germany) said Niels Ackermann resigned as CFO and a director to join Morgan Stanley. Peter Llewellyn-Davies, CEO of consulting company PLD Management Service, will serve as acting CFO. BC Staff...
Items per page:
1 - 10 of 13